Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for frail elderly lymphoma patients

NCT ID NCT07207785

Not yet recruiting Disease control Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests pirtobrutinib, a daily oral drug, as a first treatment for elderly patients (70+) with mantle cell lymphoma who are considered unfit or frail. The goal is to see if the drug can control the cancer and delay progression. 56 participants will take the drug until the disease worsens or side effects become unacceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pirtobrutinib (Jaypirca), a targeted oral drug
What this could lead to
If successful, this could offer a gentler, effective treatment option for elderly patients with mantle cell lymphoma who cannot tolerate standard chemotherapy.
What could go wrong
This is a small, early-phase study (56 participants) with no comparison group. The drug may not control the cancer long-term, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

  • A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di Ematologia

    Palermo, Italy

  • A.O. S. Maria di Terni - S.C. Oncoematologia

    Terni, Italy

  • AOU Integrata di Verona - U.O. Ematologia

    Verona, Italy

  • AOU Ospedali Riuniti - Clinica di Ematologia

    Ancona, Italy

  • AOU Senese - U.O.C. Ematologia

    Siena, Italy

  • ASST Spedali Civili di Brescia - Ematologia

    Brescia, Italy

  • Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico

    Avellino, Italy

  • Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Ematologia

    Catania, Italy

  • Azienda USL Piacenza - UOC Ematologia e Centro Trapianti

    Piacenza, Italy

  • Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

    Reggio Emilia, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia

    Milan, Italy

  • IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST S.R.L. - Ematologia

    Meldola, Forlì-Cesena, Italy

  • Istituto Clinico Humanitas - U.O. Ematologia

    Rozzano, Milano, Italy

  • Nuovo Ospedale degli Infermi - SSD Ematologia

    Biella, Italy

  • Ospedale Ca Foncello - S.C di Ematologia

    Treviso, Italy

  • Ospedale di Circolo - U.O.C Ematologia

    Varese, Italy

  • P.O. Spirito Santo di Pescara - UOC Ematologia Dipartimento Oncologico Ematologico - ASL Pescara

    Pescara, Italy

  • Parma - AOU di Parma - UOC Ematologia e CTMO

    Parma, Italy

  • Policlinico S.Orsola-Malpighi - Istituto di Ematologia "Seragnoli"

    Bologna, Italy

  • Vicenza - ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

    Vicenza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.